The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
(2007) · The Ocular Surface · doi:10.1016/s1542-0124(12)70081-2 · Cited by 3,267
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Self-citationHueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
The SYK tyrosine kinase: A crucial player in diverse biological functions
Mócsai, A., Ruland, J., & Tybulewicz, V. L. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2765 · Cited by 1,368
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Self-citation2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Xing, L., Dai, Z., Jabbari, A., Cerise, J. E., Higgins, C. A., Gong, W., de Jong, A., Harel, S., DeStefano, G. M., Rothman, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3645 · Cited by 987
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Self-citationInterleukin-22: Immunobiology and Pathology
Dudakov, J. A., Hanash, A. M., & van den Brink, M. R. M. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112123 · Cited by 905
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 889
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Sheai, J. J., et al. (1995) · Nature · doi:10.1038/377065a0 · Cited by 877
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development
Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., et al. (1995) · Science · doi:10.1126/science.270.5237.797 · Cited by 803
Self-citationHume, D. A., & MacDonald, K. P. A. (2012) · Blood · doi:10.1182/blood-2011-09-379214 · Cited by 763
Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA
Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., & Kuriyan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81443-9 · Cited by 720
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Self-citationModulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
Self-citationBaricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J. E., Weller, P. F., Simon, H.-U., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 583
van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Hanania, N. A., Korenblat, P., Chapman, K. R., Bateman, E. D., Kopecky, P., Paggiaro, P., Yokoyama, A., Olsson, J., Gray, S., Holweg, C. T. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30265-x · Cited by 469
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00006 · Cited by 448
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Fleischmann, R., Schiff, M., van der Heijde, D., Ramos‐Remus, C., Spindler, A., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C., de Bono, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 427
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
The IL-20 subfamily of cytokines — from host defence to tissue homeostasis
Rutz, S., Wang, X., & Ouyang, W. (2014) · Nature Reviews Immunology · doi:10.1038/nri3766 · Cited by 416
Bachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Gerlach, K., Hwang, Y., Nikolaev, A., Atreya, R., Dornhoff, H., Steiner, S., Lehr, H.-A., Wirtz, S., Vieth, M., Waisman, A., et al. (2014) · Nature Immunology · doi:10.1038/ni.2920 · Cited by 407
Dougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
FLT3 as a therapeutic target in AML: still challenging after all these years
Kindler, T., Lipka, D. B., & Fischer, T. (2010) · Blood · doi:10.1182/blood-2010-04-261867 · Cited by 384
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000500 · Cited by 381
van der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., Li, D., Menon, S., & Kanik, K. S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210322 · Cited by 376
Super-enhancers delineate disease-associated regulatory nodes in T cells
Vahedi, G., Kanno, Y., Furumoto, Y., Jiang, K., Parker, S. C. J., Erdos, M. R., Davis, S. R., Roychoudhuri, R., Restifo, N. P., Gadina, M., et al. (2015) · Nature · doi:10.1038/nature14154 · Cited by 374
Self-citationPanés, J., Sandborn, W. J., Schreiber, S., Sands, B. E., Vermeire, S., D'Haens, G., Panaccione, R., Higgins, P. D. R., Colombel, J.-F., Feagan, B. G., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312735 · Cited by 373
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89776 · Cited by 355
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu, L. Y., Craiglow, B. G., Dai, F., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.007 · Cited by 349
Volpato, S., Guralnik, J. M., Ferrucci, L., Balfour, J., Chaves, P., Fried, L. P., & Harris, T. B. (2001) · Circulation · doi:10.1161/01.cir.103.7.947 · Cited by 328
IL-6 biology: implications for clinical targeting in rheumatic disease
Calabrese, L. H., & Rose-John, S. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.127 · Cited by 328
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events
Solomon, D. H., Reed, G. W., Kremer, J. M., Curtis, J. R., Farkouh, M. E., Harrold, L. R., Hochberg, M. C., Tsao, P., & Greenberg, J. D. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39098 · Cited by 325
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Anzengruber, F., Maul, J.-T., Kamarachev, J., Trüeb, R. M., French, L. E., & Navarini, A. A. (2016) · Case Reports in Dermatology · doi:10.1159/000445182 · Cited by 304
Interleukin 10 Receptor Signaling
Shouval, D. S., Ouahed, J., Biswas, A., Goettel, J. A., Horwitz, B. H., Klein, C., Muise, A. M., & Snapper, S. B. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00005-5 · Cited by 304
Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130683 · Cited by 301
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300
Denny, M. F., Thacker, S., Mehta, H., Somers, E. C., Dodick, T., Barrat, F. J., McCune, W. J., & Kaplan, M. J. (2007) · Blood · doi:10.1182/blood-2007-05-089086 · Cited by 282
Interleukin-1 function and role in rheumatic disease
Schett, G., Dayer, J.-M., & Manger, B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.166 · Cited by 279
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 264
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Hak, A. E., Karlson, E. W., Feskanich, D., Stampfer, M. J., & Costenbader, K. H. (2009) · Arthritis Care & Research · doi:10.1002/art.24537 · Cited by 262
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow, B. G., & King, B. A. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1520 · Cited by 259
Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., Dainichi, T., Honda, T., Otsuka, A., Kimoto, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.051 · Cited by 259
Lippert, E., Boissinot, M., Kralovics, R., Girodon, F., Dobo, I., Praloran, V., Boiret-Dupré, N., Skoda, R. C., & Hermouet, S. (2006) · Blood · doi:10.1182/blood-2006-01-013540 · Cited by 234
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach-Mansky, R., Christiano, A. M., Clynes, R., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.015 · Cited by 233
Van Rompaey, L., Galien, R., van der Aar, E. M., Clement-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 231
Havrdová, E., Belova, A., Goloborodko, A., Tisserant, A., Wright, A., Wallstroem, E., Garren, H., Maguire, R. P., & Johns, D. R. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8128-x · Cited by 224
Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., Checchio, T., Tensfeldt, T. G., Hoffman, E., Riese, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0880-2 · Cited by 223
Shi, J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., Punwani, N., Williams, W. V., & Yeleswaram, S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.354 · Cited by 222
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Furumoto, Y., Smith, C. K., Blanco, L., Zhao, W., Brooks, S. R., Thacker, S. G., Zarzour, A., Sciumè, G., Tsai, W. L., Trier, A. M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39818 · Cited by 217
Self-citationTelliez, J.-B., Dowty, M. E., Wang, L., Jussif, J., Lin, T., Li, L., Moy, E., Balbo, P., Li, W., Zhao, Y., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00677 · Cited by 204
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., & Zerwes, H.-G. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.012 · Cited by 200
Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39808 · Cited by 200
Mok, C. C., Ko, G. T. C., Ho, L. Y., Yu, K. L., Chan, P. T., & To, C. H. (2011) · Arthritis Care & Research · doi:10.1002/acr.20363 · Cited by 199
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
Charles‐Schoeman, C., Fleischmann, R., Davignon, J., Schwartz, H., Turner, S. M., Beysen, C., Milad, M., Hellerstein, M. K., Luo, Z., Kaplan, I. V., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38974 · Cited by 188
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Punwani, N., Scherle, P., Flores, R., Shi, J., Liang, J., Yeleswaram, S., Levy, R., Williams, W., & Gottlieb, A. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.12.018 · Cited by 185
Kremer, J. M., Emery, P., Camp, H. S., Friedman, A., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S., & Keystone, E. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39801 · Cited by 182
Origin and Function of Circulating Plasmablasts during Acute Viral Infections
Fink, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00078 · Cited by 181
IL-9 and its receptor are predominantly involved in the pathogenesis of UC
Nalleweg, N., Chiriac, M. T., Podstawa, E., Lehmann, C., Rau, T. T., Atreya, R., Krauss, E., Hundorfean, G., Fichtner-Feigl, S., Hartmann, A., et al. (2015) · Gut · doi:10.1136/gutjnl-2013-305947 · Cited by 181
Advances in kinase targeting: current clinical use and clinical trials
Rask-Andersen, M., Zhang, J., Fabbro, D., & Schiöth, H. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.007 · Cited by 181
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow, B. G., Liu, L. Y., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.006 · Cited by 179
Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy
Waldmann, T. A., & Chen, J. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110416-120628 · Cited by 171
Shimozaki, K., Nakajima, K., Hirano, T., & Nagata, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25184 · Cited by 169
Vincenti, F., Tedesco Silva, H., Busque, S., O’Connell, P., Friedewald, J., Cibrik, D., Budde, K., Yoshida, A., Cohney, S., Weimar, W., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04127.x · Cited by 168
Xie, F., Yun, H., Bernatsky, S., & Curtis, J. R. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39761 · Cited by 161
Souto, A., Salgado, E., Maneiro, J. R., Mera, A., Carmona, L., & Gómez‐Reino, J. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38894 · Cited by 160
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Hornung, T., Janzen, V., Heidgen, F.-J., Wolf, D. G. F., Bieber, T. R. M., & Wenzel, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412997 · Cited by 156
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. A., Follis, S. L., King, V. I., Tena, J., & Stegemann, M. R. (2013) · Veterinary Dermatology · doi:10.1111/vde.12088 · Cited by 155
The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models
Kudlacz, E. M., Perry, B. D., Sawyer, P. S., Conklyn, M. J., McCurdy, S. P., Brissette, W. H., and, M. F., & Changelian, P. S. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00281.x · Cited by 154
Yamanaka, H., Tanaka, Y., Takeuchi, T., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0932-2 · Cited by 154
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 152
Bissonnette, R., Iversen, L., Sofen, H. L., Griffiths, C. E. M., Foley, P. A., Romiti, R., Bachinsky, M., Rottinghaus, S. T., Tan, H., Proulx, J., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13551 · Cited by 151
Gao, W., McGarry, T., Orr, C., McCormick, J., Veale, D. J., & Fearon, U. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207201 · Cited by 149
Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
Martinꝉ, R., Sospedra, M., Rosito, M., & Engelhardt, B. (2016) · European Journal of Immunology · doi:10.1002/eji.201646485 · Cited by 148
Radner, H., Lesperance, T., Accortt, N. A., & Solomon, D. H. (2016) · Arthritis Care & Research · doi:10.1002/acr.23171 · Cited by 148
Charles‐Schoeman, C., Wicker, P. A., González-Gay, M. Á., Boy, M. G., Zuckerman, A. L., Soma, K., Geier, J. L., Kwok, K. K., & Riese, R. J. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.05.014 · Cited by 146
IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue
Leung, J. M., Davenport, M., Wolff, M. J., Wiens, K. E., Abidi, W. M., Poles, M. A., Cho, I., Ullman, T. A., Mayer, L., & Loke, P. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.31 · Cited by 145
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
Milici, A. J., Kudlacz, E. M., Audoly, L., Zwillich, S. H., & Changelian, P. S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2365 · Cited by 142
Krueger, J. G., Clark, J. D., Suárez‐Fariñas, M., Fuentes‐Duculan, J., Cueto, I., Wang, C. Q. F., Tan, H., Wolk, R. A., Rottinghaus, S. T., Whitley, M. Z., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1318 · Cited by 142
Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
Wathes, R., Moule, S., & Milojković, D. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302135 · Cited by 137
Cytokines and Chemokines in Irritant Contact Dermatitis
Lee, H. Y., Stieger, M., Yawalkar, N., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/916497 · Cited by 134
Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis
Tobin, A., Veale, D. J., FitzGerald, O., Rogers, S., Collins, P. M., O'Shea, D. B., & Kirby, B. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090822 · Cited by 134
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
Kurtzman, D. J. B., Wright, N. A., Lin, J., Femia, A. N., Merola, J. F., Patel, M., & Vleugels, R. A. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.0866 · Cited by 133
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Menet, C. J., Fletcher, S. R., Lommen, G. V., Geney, R., Blanc, J., Smits, K., Jouannigot, N., Deprez, P., van der Aar, E. M., Clément-Lacroix, P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501262q · Cited by 131
Genovese, M. C., van Vollenhoven, R., Pacheco‐Tena, C., Zhang, Y., & Kinnman, N. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39473 · Cited by 130
Revisiting Crohn's disease as a primary immunodeficiency of macrophages
Casanova, J., & Abel, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20091683 · Cited by 128
Charles-Schoeman, C., González-Gay, M., Kaplan, I., Boy, M., Geier, J., Luo, Z., Zuckerman, A. L., & Riese, R. (2016) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2016.03.004 · Cited by 128
An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Rao, V. U., Pavlov, A., Klearman, M., Musselman, D. R., Giles, J. T., Bathon, J. M., Sattar, N. A., & Lee, J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38920 · Cited by 119
Papp, K. A., Pariser, D. M., Catlin, M., Wierz, G., Ball, G., Akinlade, B., Zeiher, B. G., & Krueger, J. G. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13745 · Cited by 117
Topical Ruxolitinib for the Treatment of Alopecia Universalis
Craiglow, B. G., Tavares, D., & King, B. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.4445 · Cited by 115
Fleischmann, R., DAMJANOV, N. S., Kivitz, A., Legedza, A. K., Hoock, T. C., & Kinnman, N. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38949 · Cited by 114
Kivitz, A., Gutiérrez-Ureña, S. R., Poiley, J. E., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39955 · Cited by 110
Long-term activation of the innate immune system in atherosclerosis
Christ, A., Bekkering, S., Latz, E., & Riksen, N. P. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.04.004 · Cited by 107
Conaghan, P. G., Østergaard, M., Bowes, M. A., Wu, C., Fuerst, T. P., van der Heijde, D. M. F. M., Irazoque-Palazuelos, F. C., Soto‐Raices, O., Hrycaj, P., Xie, Z., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208267 · Cited by 104
Singh, J. A., Hossain, A., Ghogomu, E. T., Kotb, A., Christensen, R., Mudano, A. S., Maxwell, L. J., Shah, N. P., Tugwell, P., & Wells, G. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012183 · Cited by 104
Works, M. G., Yin, F., Yin, C., Yiu, Y. Y., Shew, K., Tran, T.-T., Dunlap, N., Lam, J. S., Mitchell, T. J., Reader, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400205 · Cited by 102
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Goedken, E. R., Argiriadi, M. A., Banach, D. L., Fiamengo, B. A., Foley, S. E., Frank, K. E., George, J. S., Harris, C. M., Hobson, A. D., Ihle, D. C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595181 · Cited by 101
Papp, K. A., Bissonnette, R., Gooderham, M., Feldman, S. R., Iversen, L., Soung, J., Draelos, Z. D., Mamolo, C. M., Purohit, V. S., Wang, C., et al. (2016) · BMC Dermatology · doi:10.1186/s12895-016-0051-4 · Cited by 101
Coffey, G., Betz, A., DeGuzman, F. R., Pak, Y., Inagaki, M., Baker, D. C., Hollenbach, S. J., Pandey, A., & Sinha, U. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218164 · Cited by 98
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Liew, S. H. M., Nichols, K. K., Klamerus, K. J., Li, J. Z., Zhang, M., & Foulks, G. N. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.01.028 · Cited by 94
Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
Smith, G. A., Uchida, K., Weiss, A., & Taunton, J. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2056 · Cited by 92
Farmer, L. J., Ledeboer, M. W., Hoock, T. C., Arnost, M. J., Bethiel, R. S., Bennani, Y. L., Black, J., Brummel, C. L., Chakilam, A. R., Dorsch, W. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00301 · Cited by 91
Ross, S. H., Rollings, C., Anderson, K. E., Hawkins, P. T., Stephens, L. R., & Cantrell, D. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.022 · Cited by 89
Ludbrook, V. J., Hicks, K. J., Hanrott, K., Patel, J., Binks, M. H., Wyres, M. R., Watson, J., Wilson, P., Simeoni, M., Schifano, L. A., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14399 · Cited by 86
He, Y., Wong, A. Y. S., Chan, E. W., Lau, W. C. Y., Man, K. K. C., Chui, C. S. L., Worsley, A. J., & Wong, I. C. K. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-298 · Cited by 79
King, B., Lee, A. I., & Choi, J. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.10.044 · Cited by 78
Lamba, M., Wang, R., Fletcher, T., et al. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.734 · Cited by 77
Strand, V., Kremer, J. M., Wallenstein, G. V., Kanik, K. S., Connell, C. A., Gruben, D. C., Zwillich, S. H., & Fleischmann, R. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0825-9 · Cited by 76
Bao, L., Shi, V. Y., & Chan, L. S. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2011.12.008 · Cited by 75
Charles‐Schoeman, C., Burmester, G. R., Nash, P. T., Zerbini, C. A. F., Soma, K., Kwok, K. K., Hendrikx, T. K., Bananis, E., & Fleischmann, R. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207178 · Cited by 75
Okiyama, N., Furumoto, Y., Villarroel, V. A., Linton, J. T., Tsai, W. L., Gutermuth, J., Ghoreschi, K., Gadina, M., O’Shea, J. J., & Katz, S. I. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.476 · Cited by 73
Self-citationA case of refractory dermatomyositis responsive to tofacitinib
Paik, J. J., & Christopher‐Stine, L. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.08.009 · Cited by 73
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
Punwani, N. G., Burn, T. C., Scherle, P., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13994 · Cited by 69
Network pharmacology of JAK inhibitors
Moodley, D., Yoshida, H., Mostafavi, S., Asinovski, N., Ortiz-Lopez, A., Symanowicz, P. T., Telliez, J., Hegen, M., Clark, J. D., Mathis, D. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610253113 · Cited by 68
Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
Szeląg, M., Piaszyk-Borychowska, A., Plens-Gałąska, M., Wesoły, J., & Bluyssen, H. A. R. (2016) · Oncotarget · doi:10.18632/oncotarget.9195 · Cited by 67
Impact of tofacitinib treatment on human B-cells in vitro and in vivo
Rizzi, M., Lorenzetti, R., Fischer, K., Staniek, J., Janowska, I., Troilo, A., Strohmeier, V., Erlacher, M., Kunze, M., Bannert, B., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.10.005 · Cited by 67
Canavan, T. N., Elmets, C. A., Cantrell, W., Evans, J. M., & Elewski, B. E. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0162-4 · Cited by 66
Kahl, L. P., Patel, J., Layton, M., Binks, M. H., Hicks, K. J., Léon, G., HACHULLA, E., Machado, D., Staumont-Sallé, D., Dickson, M. A., et al. (2016) · Lupus · doi:10.1177/0961203316640910 · Cited by 66
Strand, V., Burmester, G. R., Zerbini, C. A. F., Mebus, C. A., Zwillich, S. H., Gruben, D. C., & Wallenstein, G. V. (2014) · Arthritis Care & Research · doi:10.1002/acr.22453 · Cited by 65
Strand, V., Lee, E. B., Fleischmann, R., Alten, R., Koncz, T., Zwillich, S. H., Gruben, D. C., Wilkinson, B. E., Krishnaswami, S., & Wallenstein, G. V. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000308 · Cited by 64
Ruxolitinib‐induced reversal of alopecia universalis in a patient with essential thrombocythemia
Pieri, L., Guglielmelli, P., & Vannucchi, A. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23871 · Cited by 63
Efficacy of tofacitinib in treatment of alopecia universalis in two patients
Gupta, A., Carviel, J., & Abramovits, W. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13598 · Cited by 58
Kremer, J. M., Kivitz, A., Campos, J. A. S., Nasonov, E. L., Tony, H., Lee, S.-K., Vlahos, B. L., Hammond, C., Bukowski, J. F., Li, H., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0612-7 · Cited by 55
Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
Vincenti, F. G., Junior, H. T. S., Busque, S., O’Connell, P. J., Russ, G. R., Budde, K., Yoshida, A., Tortorici, M. A., Lamba, M., Lawendy, N., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13181 · Cited by 54
Wang, J., Devenport, J., Low, J., Yu, D.-L., & Hitraya, E. (2016) · Arthritis care & research · doi:10.1002/acr.22765 · Cited by 54
Smolen, J. S., Aletaha, D., Gruben, D. C., Zwillich, S. H., Krishnaswami, S., & Mebus, C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39996 · Cited by 54
Isaacs, J. D., Zuckerman, A. L., Krishnaswami, S., Nduaka, C. I., Lan, S.-P., Hutmacher, M. M., Boy, M. G., Kowalski, K., Menon, S. S., & Riese, R. J. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4673 · Cited by 53
William, A. D., Lee, A. C.-H., Poulsen, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201454n · Cited by 53
Genovese, M. C., Yang, F., Østergaard, M., & Kinnman, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208901 · Cited by 52
Tofacitinib for the treatment of moderate-to-severe psoriasis
Chiricozzi, A., Faleri, S., Saraceno, R., Bianchi, L., Buonomo, O. C., Chimenti, S., & Chimenti, M. S. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1013534 · Cited by 51
Molecular mechanisms of pruritus
Meng, J., & Steinhoff, M. S. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.08.006 · Cited by 48
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Herrera, A. F., & Jacobsen, E. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0010 · Cited by 46
Tofacitinib for polyarteritis nodosa: a tailored therapy
Rimar, D., Alpert, A., Starosvetsky, E., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209330 · Cited by 46
Wu, J. J., Strober, B. E., Hansen, P. R., Ahlehoff, O., Egeberg, A., Qureshi, A. A., Robertson, D. H., Valdez, H., Tan, H., & Wolk, R. A. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.06.012 · Cited by 45
Koga, T., Sato, T., Umeda, M., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.10.003 · Cited by 37
Fleischmann, R., Kremer, J. M., Tanaka, Y., Gruben, D. C., Kanik, K. S., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Wilkinson, B. E., Zwillich, S. H., et al. (2016) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12901 · Cited by 36
Amano, W., Nakajima, S., Yamamoto, Y., Tanimoto, A., Matsushita, M., Miyachi, Y., & Kabashima, K. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.09.007 · Cited by 34
SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis
Madan, B., Goh, K. C., Hart, S., William, A. D., Jayaraman, R., Ethirajulu, K., Dymock, B. W., & Wood, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200675 · Cited by 33
Landewé, R., Connell, C. A., Bradley, J. D., Wilkinson, B. E., Gruben, D. C., Strengholt, S., & van der Heijde, D. M. F. M. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1106-y · Cited by 33
Fleischmann, R., Huizinga, T. W. J., Kavanaugh, A. F., et al. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000262 · Cited by 31
Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis
Li, L., Silveira, L. J., Hamzeh, N. Y., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01469-2015 · Cited by 29
Malignancy and Janus Kinase Inhibition
Sivaraman, P., & Cohen, S. B. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.008 · Cited by 29
A Case Series on Patients on Tofacitinib in Combination With a Biologic
Barroso, N. S., Miller, E. Z., & Fürst, D. E. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000663 · Cited by 28
Cardiovascular risk factor management in patients with RA compared to matched non-RA patients
Alemao, E., Cawston, H., Bourhis, F., Al, M., Mölken, M. R., Liao, K. P., & Solomon, D. H. (2015) · Rheumatology · doi:10.1093/rheumatology/kev427 · Cited by 25
Moore, C. A., Iasella, C. J., Venkataramanan, R., Lakkis, F. G., Smith, R. B., McDyer, J. F., Zeevi, A., & Ensor, C. R. (2016) · Human Immunology · doi:10.1016/j.humimm.2016.12.005 · Cited by 25
Damsky, W., & King, B. (2016) · JAAD Case Reports · doi:10.1016/j.jdcr.2016.10.009 · Cited by 20
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2
Kettle, J. G., Åstrand, A., Catley, M. C., Grimster, N. P., Nilsson, M., Su, Q., & Woessner, R. D. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1252754 · Cited by 20
IL-17A blockade ameliorates ankylosing spondylitis
Duarte, J. H. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.7 · Cited by 17
Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Scheinberg, M. A., & Ferreira, S. B. (2016) · Annals of Internal Medicine · doi:10.7326/l16-0125 · Cited by 16
Chapin, R. E., Ball, D. J., Radi, Z. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw197 · Cited by 13
JAK–cytokine receptor recognition, unboxed
McNally, R., & Eck, M. J. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2824 · Cited by 12
Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis
Tseng, B., Amighi, A., Bradford, K., et al. (2016) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000456 · Cited by 11
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
McGregor, M. C., Krings, J. G., Nair, P., & Castro, M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1944ci · Cited by 432
Metadata
- Authors
- Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-01
- Volume
- 17
- Issue
- 1
- Pages
- 78-78
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4251944893
- Cited by
- 394
- References
- 179
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.